Healthcare -
Medical - Healthcare Information Services - NASDAQ - US
$ 7.94
2.26 %
$ 980 M
Market Cap
-5.05
P/E
1. INTRINSIC VALUE
Balance Sheet
10x Genomics, Inc.
| Current Assets | 584 M |
| Cash & Short-Term Investments | 393 M |
| Receivables | 87.9 M |
| Other Current Assets | 103 M |
| Non-Current Assets | 334 M |
| Long-Term Investments | 0 |
| PP&E | 310 M |
| Other Non-Current Assets | 24.3 M |
| Current Liabilities | 118 M |
| Accounts Payable | 12.9 M |
| Short-Term Debt | 9.29 M |
| Other Current Liabilities | 95.4 M |
| Non-Current Liabilities | 90.9 M |
| Long-Term Debt | 73.3 M |
| Other Non-Current Liabilities | 17.5 M |
EFFICIENCY
Earnings Waterfall
10x Genomics, Inc.
| Revenue | 611 M |
| Cost Of Revenue | 196 M |
| Gross Profit | 414 M |
| Operating Expenses | 609 M |
| Operating Income | -195 M |
| Other Expenses | -11.9 M |
| Net Income | -183 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
10x Genomics, Inc.
| Net Income | -183 M |
| Depreciation & Amortization | 43.7 M |
| Capital Expenditures | -12.4 M |
| Stock-Based Compensation | 141 M |
| Change in Working Capital | 1.25 M |
| Others | -8.99 M |
| Free Cash Flow | -5.73 M |
Wall Street Analysts Price Targets
10x Genomics, Inc.
Wall Street analysts predict an average 1-year price target for TXG of $30.2 , with forecasts ranging from
a
low of
$24 to a high of $46 .
TXG Lowest Price Target
Wall Street Target
24 USD
202.27%
TXG Average Price Target
Wall Street Target
30.2 USD
280.35%
TXG Highest Price Target
Wall Street Target
46 USD
479.35%
4. DIVIDEND
ANALYSIS
TXG does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
10x Genomics, Inc.
Sold
0-3 MONTHS
191 K USD 2
3-6 MONTHS
171 K USD 2
6-9 MONTHS
317 K USD 3
9-12 MONTHS
289 K USD 3
Bought
446 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Torex Gold Reports Q1 2025 Production Results
Processing plant tie-ins concluded and first copper concentrate achieved; quarterly production in line with plan (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports Q1 2025 gold equivalent ("AuEq") payable production of 59,630 ounces ("oz") and AuEq sold of 60,568 oz. The Company is on track to achieve annual payable production guidance of 400,000 to 450,000 oz AuEq1.
newsfilecorp.com
- 3 weeks ago
Vizgen Announces End of Litigation with 10x Genomics and Harvard University
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #neuroscience--Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today released an open letter in response to the settlement of litigation between Vizgen, Harvard University and 10X Genomics in the United States District Court for the District of Delaware. Dear Customers, Researchers and Friends of Vizgen: On February 5th, we secured an important settlement putting an end to litigation, including.
businesswire.com
- 4 weeks ago
Torex Gold Reports First Copper Concentrate Production from Media Luna
Processing plant tie-ins and restart complete; commercial production expected in coming weeks(All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces completion of the four-week tie-in period for the Media Luna Project ("Media Luna") and first production of precious metal-rich copper concentrate. Jody Kuzenko, President and CEO of Torex, stated: "Following almost three years to the day of the release of our feasibility study for the Media Luna Project, we have completed the tie-in period at our processing plant and achieved first production of copper concentrate.
newsfilecorp.com
- 1 month ago
10x Genomics: Lower Cost Innovation May Drive A Rebound
I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, particularly in the biopharma sector, presenting significant revenue opportunities. Despite historical underperformance and high risk, TXG's leading technologies and potential market penetration justify holding the stock at current price levels.
seekingalpha.com
- 1 month ago
Torex Gold Reports Year-End 2024 Reserves & Resources
Drilling success continues to support reserve life extensions (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to report year-end 2024 mineral reserves and resources for the Morelos Complex, which includes the producing El Limón Guajes ("ELG") Mine Complex (consisting of the ELG Open Pits and ELG Underground), Media Luna Underground mine, development phase EPO Underground deposit, and surface stockpiles. Table 1: Year-over-year comparison of mineral reserves & mineral resources for the Morelos Complex December 31, 2024 December 31, 2023 Variance Tonnes AuEq AuEq Tonnes AuEq AuEq Tonnes AuEq AuEq (kt) (gpt) (koz) (kt) (gpt) (koz) (kt) (gpt) (koz) Proven & Probable Reserves Media Luna Underground 24,180 4.26 3,311 23,569 4.43 3,360 3% (4%) (1%) ELG Underground 4,019 5.12 662 3,504 5.81 654 15% (12%) 1% EPO Underground 5,029 4.83 781 - - - na na na ELG Open Pit 945 2.69 82 5,553 3.16 565 (83%) (15%) (86%) Surface Stockpiles 6,235 1.30 261 4,972 1.20 192 25% 8% 36% Total Morelos Complex 40,408 3.92 5,096 37,598 3.95 4,771 7% (1%) 7% Measured & Indicated Resources Media Luna Underground 29,114 5.07 4,744 27,451 5.23 4,618 6% (3%) 3% ELG Underground 8,451 5.20 1,414 8,176 5.48 1,441 3% (5%) (2%) EPO Underground 7,060 5.18 1,176 6,979 5.14 1,153 1% 1% 2% ELG Open Pit 1,054 2.86 97 6,110 3.13 615 (83%) (9%) (84%) Total Morelos Complex 45,679 5.06 7,431 48,717 5.00 7,828 (6%) 1% (5%) Inferred Resources Media Luna Underground 7,675 4.12 1,017 7,330 4.25 1,001 5% (3%) 2% ELG Underground 1,961 4.30 271 2,396 5.28 407 (18%) (19%) (33%) EPO Underground 6,883 4.31 954 4,960 4.52 721 39% (5%) 32% ELG Open Pit 6 3.65 1 399 2.08 27 (98%) 75% (97%) Total Morelos Complex 16,526 4.22 2,243 15,085 4.45 2,156 10% (5%) 4% Notes to Table: 1.
newsfilecorp.com
- 1 month ago
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif. , March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.
prnewswire.com
- 1 month ago
Torex Gold Reports Excellent Drill Results from Media Luna West and Initial Results from Media Luna East
Compelling results return multiple high-grade intercepts at both Media Luna East and West (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide results from the ongoing drilling program at Media Luna West and results from initial drill testing at Media Luna East. Drilling at both targets supports the Company's exploration strategy, which is focused, in part, on unlocking additional near-mine opportunities at the Media Luna Cluster in order to further enhance and extend the production profile of the Morelos Complex.
newsfilecorp.com
- 2 months ago
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platforms PLEASANTON, Calif. , Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale.
prnewswire.com
- 2 months ago
Torex Gold Reports Q4 and Full Year 2024 Results
2024 marks another solid year of operational and financial results; on track to return to positive free cash flow generation by mid-2025 (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three months and year ended December 31, 2024. Torex will host a conference call tomorrow morning at 9:00 AM (ET) to discuss the results.
newsfilecorp.com
- 2 months ago
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
PLEASANTON, Calif. , Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m.
prnewswire.com
- 2 months ago
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).
benzinga.com
- 2 months ago
10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Adam Taich - CFO Conference Call Participants Dan Brennan - TD Cowen Patrick Donnelly - Citi Dan Arias - Stifel Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Tejas Savant - Morgan Stanley Dan Leonard - UBS Subbu Nambi - Guggenheim Securities Kyle Mikson - Canaccord Genuity Luke Sergott - Barclays Matt Larew - William Blair Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Operator Thank you for standing by. My name is [Prilla] and I will be your conference operator today.
seekingalpha.com
- 2 months ago
8. Profile
Summary
10x Genomics, Inc. TXG
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 980 M
Dividend Yield
0.00%
Description
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Contact
6230 Stoneridge Mall Road, Pleasanton, CA, 94588-3260
https://www.10xgenomics.com
IPO
Date
Sept. 12, 2019
Employees
1306
Officers
Ms. Cassie Corneau
Manager of Investor Relations & Strategic Finance
Mr. Jim Goodrich
Chief of Global Operations
Mr. Adam S. Taich
Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer
Mr. Eric S. Whitaker Esq.
Chief Legal Officer
Ms. Mennah Moustafa
Chief Commercial Officer
Dr. Serge Saxonov Ph.D.
Co-Founder, Chief Executive Officer & Director
Dr. Benjamin J. Hindson Ph.D.
Co-Founder, President, Chief Scientific Officer & Director
Mr. Alexander Wong
Chief Information Officer
Mr. Michael Schnall-Levin
Founding Scientist & Chief Technology Officer
Ms. Rebecca Port
Chief People Officer